Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.

Alba RocabertBeatriz BorjabadLeire BerrocalJordi BlanchAlexy InciarteIvan ChiviteAna Gonzalez-CordonBerta TorresJuan AmbrosioniMaria Martinez-RebollarMontserrat LagunoLorena De La MoraAlberto FoncillasAbiu SempereAna RodriguezEstela SolbesRoger LlobetJose M MiroJosep MallolasJose L BlancoElisa De LazzariEsteban Martinez

Published in: The Journal of antimicrobial chemotherapy (2023)

Switching to BIC/TAF/FTC or dolutegravir/lamivudine showed no difference in the risks of overall or toxicity-related discontinuations or in the profile of adverse events leading to discontinuation.

Keyphrases

hiv infected patients
antiretroviral therapy
open label
oxidative stress
human health
risk assessment
stem cells
clinical trial
double blind
mesenchymal stem cells
bone marrow
drug induced